Drug value assessments generally fail to account for the complexities of health care systems and thus can misinform price negotiations and lead to overly restrictive access policies. Studies have ...

This post is part of the Health Affairs Blog short series, “Value Assessment: Where Do We Go Post-COVID?” The series explores what we have learned about value assessment and related issues during the ...

A German-style fair value/pricing committee may be in the works for the United States. However, government payers still have work to do before implementing a value assessment system. The adoption of a ...

Trying to gauge the value of new drugs and devices is becoming increasingly important in the U.S. health care system, something that other countries have done explicitly for years. Pressure to get ...

A renewed commitment to patient-centered decision-making and evidence generation, combined with a focus on value, can accelerate our progress toward a true and sustained learning health system. For ...